|
NZ535320A
(en)
|
2002-02-25 |
2008-05-30 |
Elan Pharm Inc |
Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
CA2496834C
(en)
*
|
2002-09-06 |
2014-03-18 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component c5
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
SI3417875T1
(sl)
*
|
2003-02-10 |
2021-01-29 |
Biogen Ma Inc. |
Formulacija imunoglobulina in metode za njegovo pripravo
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
*
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
TR201816556T4
(tr)
*
|
2004-04-02 |
2018-11-21 |
Swedish Orphan Biovitrum Ab Publ |
Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CN103169965A
(zh)
*
|
2004-11-19 |
2013-06-26 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
|
TW200719913A
(en)
*
|
2005-03-08 |
2007-06-01 |
Pharmacia & Upjohn Co Llc |
Anti-madcam antibody compositions
|
|
US8858935B2
(en)
*
|
2005-05-19 |
2014-10-14 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
CA2625815A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-cd3 antibody formulations
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
DK2548577T3
(en)
|
2005-12-29 |
2017-03-13 |
Janssen Biotech Inc |
HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
TW200806315A
(en)
*
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
EP2066350A4
(en)
*
|
2006-09-25 |
2010-04-07 |
Medimmune Llc |
STABILIZED ANTIBODY FORMULATIONS AND THEIR USES
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
ES2925992T3
(es)
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
|
TW200837080A
(en)
*
|
2007-01-09 |
2008-09-16 |
Wyeth Corp |
Anti-IL-13 antibody formulations and uses thereof
|
|
JP5303792B2
(ja)
*
|
2007-02-12 |
2013-10-02 |
ボウジベル，ラサアド |
保存料を含まないスクラロース無菌溶液
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
US20080311119A1
(en)
*
|
2007-06-14 |
2008-12-18 |
Biogen Idec Ma Inc. |
Antibody formulations
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
ES2543735T3
(es)
*
|
2007-10-22 |
2015-08-21 |
Becton Dickinson And Company |
Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
PT2271382E
(pt)
|
2008-04-15 |
2013-05-07 |
Grifols Therapeutics Inc |
Ultrafiltração em dois andares/diafiltração
|
|
CA2734919C
(en)
|
2008-08-27 |
2016-08-16 |
Schering Corporation |
Lyophilized formulations of engineered anti-il-23p19 antibodies
|
|
TWI516501B
(zh)
*
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
AU2009319856A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Abbvie Inc. |
Stable antibody compositions and methods for stabilizing same
|
|
WO2010077045A2
(en)
*
|
2008-12-29 |
2010-07-08 |
Samyang Corporation |
Pharmaceutical composition of lyophilized formulation and preparation method of the same
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
AU2010236257A1
(en)
*
|
2009-04-17 |
2011-11-03 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
|
US20100278822A1
(en)
*
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
KR101441768B1
(ko)
*
|
2009-09-17 |
2014-09-17 |
박스터 헬쓰케어 에스에이 |
히알루로니다아제 및 면역글로불린의 안정한 복합제제, 및 그 사용방법
|
|
PL2485761T3
(pl)
*
|
2009-10-09 |
2019-10-31 |
Armagen Inc |
Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
|
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
|
CN107693791B
(zh)
*
|
2010-02-26 |
2022-06-07 |
诺沃—诺迪斯克有限公司 |
包含稳定抗体的组合物
|
|
ME02793B
(me)
|
2010-04-16 |
2018-01-20 |
Biogen Ma Inc |
Anti-vla-4 antitijela
|
|
US20130136733A1
(en)
|
2010-05-28 |
2013-05-30 |
Novo Nordisk A/S |
Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
|
|
US9095567B2
(en)
|
2010-06-04 |
2015-08-04 |
Wyeth Llc |
Vaccine formulations
|
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
CA2810734A1
(en)
|
2010-09-17 |
2012-03-22 |
Baxter International Inc. |
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
|
|
HUE069586T2
(hu)
|
2010-10-01 |
2025-03-28 |
Modernatx Inc |
Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
|
|
HRP20241666T1
(hr)
|
2010-10-25 |
2025-02-14 |
Biogen Ma Inc. |
Metode za određivanje razlika u alfa-4 integrinskoj aktivnosti pomoću korelacijskih razlika u razinama svcam i/ili smadcam
|
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EP2691112B1
(en)
|
2011-03-31 |
2018-05-23 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
KR20140033171A
(ko)
*
|
2011-05-26 |
2014-03-17 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
비활성화된 뎅기 바이러스 백신
|
|
CA2840711C
(en)
*
|
2011-07-01 |
2023-10-17 |
Biogen Idec Ma Inc. |
Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DK3682905T3
(da)
|
2011-10-03 |
2022-02-28 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
CN104169299B
(zh)
*
|
2012-01-23 |
2018-06-05 |
瑞泽恩制药公司 |
含抗Ang-2 抗体的稳定化制剂
|
|
EP3431104A1
(en)
*
|
2012-03-26 |
2019-01-23 |
Sanofi |
Stable igg4 binding agent formulations
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
JP6189415B2
(ja)
|
2012-04-02 |
2017-08-30 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
PT3071237T
(pt)
|
2013-11-21 |
2024-08-26 |
Genmab As |
Formulação liofilizada de conjugados anticorpo-fármaco
|
|
US9932591B2
(en)
|
2013-12-18 |
2018-04-03 |
University Of Delaware |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
TWI752912B
(zh)
*
|
2015-07-17 |
2022-01-21 |
美商寇西勒斯生物科技股份有限公司 |
那他珠單抗的穩定水性調配物
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
NZ744185A
(en)
|
2015-12-30 |
2025-09-26 |
Kodiak Sciences Inc |
Antibodies and conjugates thereof
|
|
ES2983242T3
(es)
|
2016-01-13 |
2024-10-22 |
Genmab As |
Formulación para anticuerpo y conjugado de fármaco del mismo
|
|
US10914720B2
(en)
|
2016-02-10 |
2021-02-09 |
Becton Dickinson France |
Method to evaluate the stability of a protein-based formulation
|
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
BR112019022873A8
(pt)
|
2017-05-02 |
2023-04-11 |
Merck Sharp & Dohme |
Formulação, e, vaso ou dispositivo de injeção.
|
|
ES2938608T3
(es)
*
|
2017-09-20 |
2023-04-13 |
Tillotts Pharma Ag |
Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
|
|
KR102686858B1
(ko)
|
2017-12-06 |
2024-07-19 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
|
|
WO2019110823A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
US20190269757A1
(en)
|
2018-03-05 |
2019-09-05 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
WO2019173767A1
(en)
|
2018-03-08 |
2019-09-12 |
Coherus Biosciences Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
CN112243379A
(zh)
*
|
2018-04-10 |
2021-01-19 |
雷迪博士实验室有限公司 |
稳定的抗体制剂
|
|
EP3773696A4
(en)
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Stable formulations of therapeutic antibody
|
|
EP3773694A4
(en)
*
|
2018-04-10 |
2021-12-29 |
Dr. Reddy's Laboratories Ltd. |
Antibody formulation
|
|
UA130009C2
(uk)
|
2018-05-07 |
2025-10-15 |
Генмаб А/С |
Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
|
|
EP3800999A4
(en)
|
2018-06-04 |
2022-06-01 |
Biogen MA Inc. |
ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
|
|
BR112020025001A2
(pt)
|
2018-06-08 |
2021-03-23 |
Argenx Bvba |
composições e métodos para o tratamento da trombocitopenia imune
|
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
US12171764B2
(en)
|
2018-06-20 |
2024-12-24 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
US20230033021A1
(en)
|
2018-06-20 |
2023-02-02 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
KR20210024082A
(ko)
*
|
2018-06-25 |
2021-03-04 |
제이씨알 파마 가부시키가이샤 |
단백질 함유 수성 액제
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
MA55149A
(fr)
|
2018-11-20 |
2021-09-29 |
Janssen Biotech Inc |
Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
|
|
CN113453708B
(zh)
|
2018-12-19 |
2025-02-21 |
默沙东有限责任公司 |
包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
|
|
EP3903815A4
(en)
|
2018-12-24 |
2022-09-28 |
Grand Theravac Life Science (Nanjing) Co., Ltd. |
Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
|
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
|
CA3138072A1
(en)
*
|
2019-06-07 |
2020-12-10 |
Argenx Bvba |
Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
|
|
KR20220019756A
(ko)
*
|
2019-06-11 |
2022-02-17 |
마크로제닉스, 인크. |
이중특이적 디아바디의 제약학적 제제 및 그것의 용도
|
|
EP4007605A4
(en)
*
|
2019-08-01 |
2023-08-16 |
Momenta Pharmaceuticals, Inc. |
ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021124793A1
(ja)
*
|
2019-12-16 |
2021-06-24 |
ニプロ株式会社 |
凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
|
|
EP4454711A3
(en)
|
2020-01-08 |
2025-01-08 |
argenx BV |
Methods for treating pemphigus disorders
|
|
IL294461A
(en)
*
|
2020-01-13 |
2022-09-01 |
Aptevo Res & Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
AU2021213153A1
(en)
*
|
2020-01-29 |
2022-08-04 |
Merck Sharp & Dohme Llc |
Methods of separating host cell lipases from an anti-LAG3 antibody production
|
|
JP2023528265A
(ja)
|
2020-05-21 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ－２３に対する抗体及びｔｎｆアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法
|
|
EP4243859A4
(en)
*
|
2020-11-12 |
2024-10-16 |
Dr. Reddy's Laboratories Ltd. |
STABLE AQUEOUS FORMULATION WITH HIGH CONCENTRATION OF ANTI-INTEGRIN ANTIBODY
|
|
AU2023236910A1
(en)
|
2022-03-14 |
2024-08-01 |
LamKap Bio gamma AG |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
IL317653A
(en)
|
2022-06-15 |
2025-02-01 |
argenx BV |
FCRN/HSA binding molecules and methods of using them
|
|
TW202504919A
(zh)
|
2023-05-30 |
2025-02-01 |
美商派拉岡醫療公司 |
α4β7整合素抗體組合物及使用方法
|